Similarly to observations reported in colon cancer cells, we found inhibition of the MAPK/ERK signalling pathway by MEK1/2-specific inhibitor U0126 to reduce SP, possibly through altering ABCG2 expression or localisation [42]. Here, MAP2K1 is linked to malignant colon neoplasm.